IBDEI2U9 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,45278,2)
 ;;=^5002524
 ;;^UTILITY(U,$J,358.3,45279,0)
 ;;=E09.42^^172^2262^11
 ;;^UTILITY(U,$J,358.3,45279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45279,1,3,0)
 ;;=3^DM drug-induced w/ neurological compl w/ diabetic polyneuropathy
 ;;^UTILITY(U,$J,358.3,45279,1,4,0)
 ;;=4^E09.42
 ;;^UTILITY(U,$J,358.3,45279,2)
 ;;=^5002566
 ;;^UTILITY(U,$J,358.3,45280,0)
 ;;=E10.42^^172^2262^4
 ;;^UTILITY(U,$J,358.3,45280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45280,1,3,0)
 ;;=3^DM Type 1 w/ diabetic polyneuropathy
 ;;^UTILITY(U,$J,358.3,45280,1,4,0)
 ;;=4^E10.42
 ;;^UTILITY(U,$J,358.3,45280,2)
 ;;=^5002606
 ;;^UTILITY(U,$J,358.3,45281,0)
 ;;=E10.65^^172^2262^5
 ;;^UTILITY(U,$J,358.3,45281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45281,1,3,0)
 ;;=3^DM Type 1 w/ hyperglycemia
 ;;^UTILITY(U,$J,358.3,45281,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,45281,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,45282,0)
 ;;=E10.9^^172^2262^6
 ;;^UTILITY(U,$J,358.3,45282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45282,1,3,0)
 ;;=3^DM Type 1 w/o complications
 ;;^UTILITY(U,$J,358.3,45282,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,45282,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,45283,0)
 ;;=E11.42^^172^2262^7
 ;;^UTILITY(U,$J,358.3,45283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45283,1,3,0)
 ;;=3^DM Type 2 w/ diabetic polyneuropathy
 ;;^UTILITY(U,$J,358.3,45283,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,45283,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,45284,0)
 ;;=E11.65^^172^2262^8
 ;;^UTILITY(U,$J,358.3,45284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45284,1,3,0)
 ;;=3^DM Type 2 w/ hyperglycemia
 ;;^UTILITY(U,$J,358.3,45284,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,45284,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,45285,0)
 ;;=E11.9^^172^2262^9
 ;;^UTILITY(U,$J,358.3,45285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45285,1,3,0)
 ;;=3^DM Type 2 w/o complications
 ;;^UTILITY(U,$J,358.3,45285,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,45285,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,45286,0)
 ;;=E13.42^^172^2262^12
 ;;^UTILITY(U,$J,358.3,45286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45286,1,3,0)
 ;;=3^DM oth w/ diabetic polyneuropathy
 ;;^UTILITY(U,$J,358.3,45286,1,4,0)
 ;;=4^E13.42
 ;;^UTILITY(U,$J,358.3,45286,2)
 ;;=^5002686
 ;;^UTILITY(U,$J,358.3,45287,0)
 ;;=E16.2^^172^2262^22
 ;;^UTILITY(U,$J,358.3,45287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45287,1,3,0)
 ;;=3^Hypoglycemia, unspecified
 ;;^UTILITY(U,$J,358.3,45287,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,45287,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,45288,0)
 ;;=E46.^^172^2262^26
 ;;^UTILITY(U,$J,358.3,45288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45288,1,3,0)
 ;;=3^Malnutrition, protein-calorie, unspec
 ;;^UTILITY(U,$J,358.3,45288,1,4,0)
 ;;=4^E46.
 ;;^UTILITY(U,$J,358.3,45288,2)
 ;;=^5002790
 ;;^UTILITY(U,$J,358.3,45289,0)
 ;;=E53.8^^172^2262^31
 ;;^UTILITY(U,$J,358.3,45289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45289,1,3,0)
 ;;=3^Vitamin B group deficiency
 ;;^UTILITY(U,$J,358.3,45289,1,4,0)
 ;;=4^E53.8
 ;;^UTILITY(U,$J,358.3,45289,2)
 ;;=^5002797
 ;;^UTILITY(U,$J,358.3,45290,0)
 ;;=E66.01^^172^2262^27
 ;;^UTILITY(U,$J,358.3,45290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,45290,1,3,0)
 ;;=3^Obesity, morbid
 ;;^UTILITY(U,$J,358.3,45290,1,4,0)
 ;;=4^E66.01
 ;;^UTILITY(U,$J,358.3,45290,2)
 ;;=^5002826
 ;;^UTILITY(U,$J,358.3,45291,0)
 ;;=E66.9^^172^2262^28
